LONG-TERM OUTCOMES OF SENTINEL LYMPH NODE BIOPSY VERSUS LYMPH NODE OBSERVATION IN MELANOMA PATIENTS. / ВІДДАЛЕНІ РЕЗУЛЬТАТИ БІОПСІЇ СТОРОЖОВОГО ЛІМФАТИЧНОГО ВУЗЛА В ПОРІВНЯННІ ЗІ СПОСТЕРЕЖЕННЯМ ЗА ЛІМФАТИЧНИМИ ВУЗЛАМИ У ПАЦІЄНТІВ З МЕЛАНОМОЮ.

OBJECTIVE: evaluating the influence of sentinel lymph node biopsy without following completion lymph node dissection independent on sentinel lymph node status on the outcome in patients with skin melanoma. MATERIALS AND METHODS: Three hundred nine patients with a primary skin melanoma were randomly assigned to wide excision of the primary tumor and sentinel lymph node biopsy without following completion lymph-node dissection independent on sentinel lymph node status or to wide excision of skin melanoma. Low-dose interferon was administrated in the adjuvant setting. RESULTS: 5-year disease-free survival rate was (85.1 ± 3.0) % in the wide excision and sentinel lymph node biopsy group and (78.4 ± 2.4) % in the wide excision group (hazard ratio, 0.69; p = 0.006). 5-year overall survival rates were similar in the two groups: (88.6 ± 3.0) % vs. (85.1 ± 2.4) %, respectively; hazard ratio, 0.97; p = 0.42. CONCLUSION: Sentinel lymph node biopsy in patients with skin melanoma increases disease-free survival rate without influence on overall survival, confirming the diagnostic, not therapeutical, value of this procedure.

RADIONUCLIDE THERAPY FOR BONE LESIONS IN CASTRATION-RESISTANT PROSTATE CANCER (STATE-OF-THE-ART LITERATURE REVIEW). / RADIONUKLIDNA TERAPIIa URAZhENNIa KISTOK U KhVORYKh NA KASTRATsIINO-REZYSTENTNYI RAK PEREDMIKhUROVOÏ ZALOZY (STAN PROBLEMY V LITERATURI).

The scope of scientific literature was reviewed to summarize the data on the 223Radichloride therapy for castration resistant forms of prostate cancer. Key advantages of the alphaemitters over betaemitting radionuclides are highlighted in the treatment of hormoneresistant bone metastases. Data demonstrating an association between the 223Radichloride treatment effectiveness and absorbed therapeutic doses were analyzed. Dependence between the 223Ra and 18Ffluoride absorbed doses in bone metastases was evaluated, which should be taken into account in a positron emission tomography monitoring. Results of studies examining the uptake of 18Ffluoride to predict the 223Radichloride accumulation during the first course of treatment were analyzed. Research areas requiring further concern have been identified through the literature review, namely: study of the relationship between an absorbed dose and other clinically relevant endpoints, including pain index, changes in alkaline phosphatase or prostate antigen levels, survival rates, and development of alternative treatment regimens depending on the therapeutic radiopharmaceutical dose.

ANALGESIC EFFECT OF VARIOUS RADIOPHARMACEUTICALS IN THE COMPLEX TREATMENT OF METASTATIC BONE DISEASE. / ZNEBOLIuVAL'NYI VPLYV RIZNYKh RADIOFARMPREPARATIV U KOMPLEKSNOMU LIKUVANNI METASTATYChNOGO URAZhENNIa KISTOK.

OBJECTIVE: The study objective was to investigate and compare the effectiveness of different radiopharmaceuticalsin the treatment of metastatic bone disease. MATERIALS AND METHODS: Cancer patients (n = 150, average age (55 ± 11.6) years, 95 females, 55 males) having gotvarious primary tumors and metastatic bone disease were given medical treatment at the Department of NuclearMedicine of the National Institute of Cancer. The 153Sm, 32Р, and 89Sr radiopharmaceutical agents produced by the«Radiopreparats¼ enterprise (Republic of Uzbekistan) and Radioisotope Centre Polatom (National Centre for NuclearResearch, Poland) were administered to the patients. There were cases of breast cancer (n = 75), prostate cancer(n = 45), lung cancer (n = 10), kidney cancer (n = 4), cervical cancer (n = 5), and rectosigmoid cancer (n = 11) amongthe treated subjects. In 135 patients (90 %) the bone metastases were detected by osteoscintigraphy with 99мTc- mo-nodiphosphonate. In 15 cases the diagnosis of metastatic bone disease was verified by other radiology methods. RESULTS: The pain intensity rating scale (LACOMED) was used to assay the analgesic effect of various radiopharma-ceuticals in metastatic bone disease. Results of treatment with 32P, 89Sr, and 153Sm were included in a comparativeanalysis procedure. It was established that the level of pain syndrome ranged from 7-8 points on the LACOMED scalebefore treatment. Upon administration of radionuclide therapy the level of pain was reduced down to 3-5 points,namely with 32P therapy it has decreased by 30.7 %, with 89Sr by 33.2 %, and with 153Sm by 41.5 % respectively. Timepattern of 153Sm analgesic effectiveness was studied depending on the number of treatment sessions. The best valueof analgesic effect of 153Sm was registered after the first treatment session with a tendency to decrease after the sec-ond and significantly lower analgesic effects after the third session. Tolerance of 153Sm was rated on the CTCNCA (v)4.3 scale. The best tolerance was peculiar to 153Sm corresponding to the «good¼ level according to a point assess-ment. When using 89Sr the drug tolerance was lower, not requiring however the drug discontinuation. The 32P radio-pharmaceutical featured the lowest tolerance approaching the «satisfactory¼ rating. In 11 patients upon that theside effects were found significantly impairing the patient's status, accordingly some extra measures were required.No decision to cancel the drug administration was made. CONCLUSIONS: Radionuclide therapy with 153Sm-oxabiphor agent can be used in the complex treatment of metastat-ic bone disease in cancer patients having got tumors of different localization. 153Sm-oxabiphor is the most effectiveand best tolerable radiopharmaceutical agent in the pain treatment in metastatic bone disease in comparison with32P and 89Sr preparations (р < 0.05).

RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER. / RADIONUKLIDNYI DIAGNOSTYChNYI ALGORYTM DLIa VYIaVLENNIa RETsYDYVIV I METASTAZIV U KhVORYKh Z IOD-NEGATYVNYMY FORMAMY DYFERENTsIIOVANOGO RAKU ShchYTOPODIBNOÏ ZALOZY.

OBJECTIVE: Developing of algorithm for the post-surgical management of patients with iodine-negative metastasesof differentiated thyroid cancer (DTC). MATERIALS AND METHODS: The DTC patients with iodine-negative metastases (n = 115) were enrolled in the study.Of them the whole body scintigraphy (WBS) was performed with technetium-99m-hexakis-2-methoxyisobutylisonitrile(99mTc-MIBI) (n = 30), WBS with technetium-99m dimercaptosuccinic acid (99mTc-DMSA) (n = 30), 18FDG PET (n = 30), andcomputer tomography (CT-scan) (n = 25). Complex 99mTc-pertechnetate scans including the dynamic and static scintigraphy was performed supplementary to 99mTc-MIBI WBS in 10 patients to obtain the angiographic curves from DTCmetastatic foci. The non-radioiodine radiopharmaceutical technologies, namely the labeled 99mTc-MIBI, 99mTc-DMSA, 99mTc-pertechnetate, and 18FDG were applied to detect the iodine-negative DTC metastases. Radioisotopic examinationswere performed at the dual-head gamma camera (Mediso Medical Imaging Systems Ltd., Hungary) and single photonemission computed tomography (SPECT) scanner «E.CAM¼ (Siemens, Germany). PET/CT scans were performed on the«Biograph 64 TruePoint¼ imaging platform (Siemens, Germany) in accordance with the European Association of NuclearMedicine (EANM) recommendations for the Siemens imaging devices with 3D-mode data acquisition. RESULTS: The conducted research suggested that it is feasible to use the non-radioiodine (99mTc-MIBI and 99mTc-DMSA)radiopharmaceutical technologies to detect the iodine-negative DTC metastases. 18FDG PET is a highly informativetechnology for the detection of iodine-negative DTC metastases in case of lung involvement in the process. Compareof the non-radioiodine radiopharmaceuticals, CT scan and 18FDG-PET/CT indicated the highest sensitivity of 18FDGPET/CT (p < 0.05). WBS with 99mTc-MIBI and 99mTc-DMSA featured the highest specificity (100 %, p < 0.05). X-ray CTis marked by the significantly lower either sensitivity, specificity, and accuracy rate (p > 0.05). Developing andapplication of algorithm for the post-surgical management of patients with iodine-negative forms of DTC will allowfor the betimes detection of relapses and metastases with administration of adequate surgical, radiation, and targeted treatment. CONCLUSIONS: Obtained results offer the opportunity to optimize the post-surgical management of patients withiodine-negative DTC forms using the options of radionuclide diagnostics with non-radioiodine radiopharmaceuticals. The latter are readily available providing the cost-cutting of diagnostic support in these patients. Place ofmorphological methods of diagnosis is determined and stage of monitoring of patients with the iodine-negativemetastases is established. Possibility of the 18FDG-PET tests for the early diagnosis of iodine-negative metastases inDTC for the first time have been studied and substantiated in Ukraine. A comprehensive radiation algorithm for thelong-term monitoring of this category of patients will allow the timely detection of recurrences and metastases ofDTC and appropriate surgery, radiation and targeted therapy administration. Data obtained as a result of the studyallowed to improve the overall and recurrence-free survival rates in the able-bodied DTC patients and reduce thecosts of follow-up of patients with iodine-negative forms of DTC.